[Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director Herve Hoppenot was granted a stock option on 10/06/2025 to buy 36,000 shares of common stock at an exercise price of $27.52 per share. The option vests monthly at 1/36 of the award beginning on 11/06/2025 and on each monthly anniversary thereafter, subject to continued service, and expires on 10/05/203536,000 options directly. The filing was signed by an attorney-in-fact on 10/07/2025.

Positive

• 36,000 stock options granted to a director, aligning management with shareholder outcomes
• Option vests monthly (1/36) beginning 11/06/2025, supporting retention
• Long expiration (10/05/2035) gives time for potential share-price appreciation

Negative

• None.

Insights

Corporate Governance Analyst

Director received a standard long-term equity award to align interests.

Granting 36,000 options at $27.52 ties the director's compensation to future share performance over a roughly ten-year horizon to the expiration date of 10/05/2035.

The monthly 1/36 vesting schedule beginning 11/06/2025 conditions value on continued service; monitor executive departures or additional grants over the next 12 months for governance signal.

Compensation Analyst

Vesting and strike details indicate multi-year retention focus.

The exercise price of $27.52 and the extended expiration provide potential upside only if the share price rises above the strike before 10/05/2035. The award vests monthly, creating a steady retention mechanism rather than a single cliff.

Investors may watch reported share counts or future equity compensation disclosures to assess dilution; the filing shows the immediate incremental grant amount of 36,000 options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoppenot Herve

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.52	10/06/2025		A		36,000		(1)	10/05/2035	Common Stock	36,000	$0	36,000	D

Explanation of Responses:

1. The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on November 6, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Maze Therapeutics (MAZE) report on the Form 4 filed 10/07/2025?

Director Herve Hoppenot was granted an option to buy 36,000 shares at $27.52 per share with monthly vesting beginning 11/06/2025 and expiration 10/05/2035.

When does the option grant to MAZE's director begin vesting?

Vesting begins on 11/06/2025 and vests monthly at 1/36 of the total award, subject to continued service.

What is the exercise price and expiration of the option reported for MAZE?

The exercise price is $27.52 per share and the option expires on 10/05/2035.

How many options does the reporting person own after the transaction?

Following the reported acquisition, the reporting person beneficially owns 36,000 options directly.

Who signed the Form 4 for this transaction?

The filing was signed by Courtney Phillips as attorney-in-fact on 10/07/2025.